ID   PPP5_RAT                Reviewed;         499 AA.
AC   P53042;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   22-JUL-2015, entry version 129.
DE   RecName: Full=Serine/threonine-protein phosphatase 5;
DE            Short=PP5;
DE            EC=3.1.3.16;
DE   AltName: Full=Protein phosphatase T;
DE            Short=PPT;
GN   Name=Ppp5c;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Testis;
RX   PubMed=8077208;
RA   Becker W., Kentrup H., Klumpp S., Schultz J.E., Joost H.G.;
RT   "Molecular cloning of a protein serine/threonine phosphatase
RT   containing a putative regulatory tetratricopeptide repeat domain.";
RL   J. Biol. Chem. 269:22586-22592(1994).
RN   [2]
RP   FUNCTION AS PHOSPHATASE, ENZYME REGULATION, AND MUTAGENESIS OF GLU-29;
RP   LYS-32; GLU-56; ILE-63; ARG-74; GLU-76; CYS-77; TYR-80; LYS-97 AND
RP   ARG-101.
RX   PubMed=11523989; DOI=10.1021/bi010999i;
RA   Kang H., Sayner S.L., Gross K.L., Russell L.C., Chinkers M.;
RT   "Identification of amino acids in the tetratricopeptide repeat and C-
RT   terminal domains of protein phosphatase 5 involved in autoinhibition
RT   and lipid activation.";
RL   Biochemistry 40:10485-10490(2001).
RN   [3]
RP   COFACTOR, ENZYME REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=11969423; DOI=10.1021/bi016090h;
RA   Ramsey A.J., Chinkers M.;
RT   "Identification of potential physiological activators of protein
RT   phosphatase 5.";
RL   Biochemistry 41:5625-5632(2002).
RN   [4]
RP   FUNCTION AS PHOSPHATASE, INTERACTION WITH GNA12 AND GNA13, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=12176367; DOI=10.1016/S0960-9822(02)01034-5;
RA   Yamaguchi Y., Katoh H., Mori K., Negishi M.;
RT   "Galpha(12) and Galpha(13) interact with Ser/Thr protein phosphatase
RT   type 5 and stimulate its phosphatase activity.";
RL   Curr. Biol. 12:1353-1358(2002).
RN   [5]
RP   FUNCTION IN DEPHOSPHORYLATING MAPT, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=15546861; DOI=10.1074/jbc.M410775200;
RA   Liu F., Iqbal K., Grundke-Iqbal I., Rossie S., Gong C.X.;
RT   "Dephosphorylation of tau by protein phosphatase 5: impairment in
RT   Alzheimer's disease.";
RL   J. Biol. Chem. 280:1790-1796(2005).
RN   [6]
RP   FUNCTION IN MAPK SIGNALING.
RX   PubMed=16892053; DOI=10.1038/ncb1465;
RA   von Kriegsheim A., Pitt A., Grindlay G.J., Kolch W., Dhillon A.S.;
RT   "Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5.";
RL   Nat. Cell Biol. 8:1011-1016(2006).
RN   [7]
RP   FUNCTION IN RAC1 SIGNALING, ENZYME REGULATION, INTERACTION WITH RAC1,
RP   AND MUTAGENESIS OF LYS-93; LYS-126 AND TYR-451.
RX   PubMed=16549782; DOI=10.1073/pnas.0600080103;
RA   Gentile S., Darden T., Erxleben C., Romeo C., Russo A., Martin N.,
RA   Rossie S., Armstrong D.L.;
RT   "Rac GTPase signaling through the PP5 protein phosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5202-5206(2006).
RN   [8]
RP   INTERACTION WITH CRY1 AND CRY2.
RX   PubMed=16790549; DOI=10.1073/pnas.0604138103;
RA   Partch C.L., Shields K.F., Thompson C.L., Selby C.P., Sancar A.;
RT   "Posttranslational regulation of the mammalian circadian clock by
RT   cryptochrome and protein phosphatase 5.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10467-10472(2006).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 16-499 IN COMPLEX WITH
RP   MAGNESIUM, AND COFACTOR.
RA   Haslbeck V., Helmuth M., Alte F., Popowicz G., Schmidt W., Weiwad M.,
RA   Fischer G., Gemmecker G., Sattler M., Striggow F., Groll M.,
RA   Richter K.;
RT   "Selective targeting of the autoinhibition of PP5 reduces tau
RT   phosphorylation in mouse.";
RL   Submitted (FEB-2013) to the PDB data bank.
CC   -!- FUNCTION: Serine/threonine-protein phosphatase that
CC       dephosphorylates a myriad of proteins involved in different
CC       signaling pathways including the kinases CSNK1E, ASK1/MAP3K5,
CC       PRKDC and RAF1, the nuclear receptors NR3C1, PPARG, ESR1 and ESR2,
CC       SMAD proteins and TAU/MAPT. Implicated in wide ranging cellular
CC       processes, including apoptosis, differentiation, DNA damage
CC       response, cell survival, regulation of ion channels or circadian
CC       rhythms, in response to steroid and thyroid hormones, calcium,
CC       fatty acids, TGF-beta as well as oxidative and genotoxic stresses.
CC       Participates in the control of DNA damage response mechanisms such
CC       as checkpoint activation and DNA damage repair through, for
CC       instance, the regulation ATM/ATR-signaling and dephosphorylation
CC       of PRKDC and TP53BP1. Inhibits ASK1/MAP3K5-mediated apoptosis
CC       induced by oxidative stress. Plays a positive role in
CC       adipogenesis, mainly through the dephosphorylation and activation
CC       of PPARG transactivation function. Also dephosphorylates and
CC       inhibits the anti-adipogenic effect of NR3C1. Regulates the
CC       circadian rhythms, through the dephosphorylation and activation of
CC       CSNK1E. May modulate TGF-beta signaling pathway by the regulation
CC       of SMAD3 phosphorylation and protein expression levels.
CC       Dephosphorylates and may play a role in the regulation of
CC       TAU/MAPT. Through their dephosphorylation, may play a role in the
CC       regulation of ions channels such as KCNH2.
CC       {ECO:0000269|PubMed:11523989, ECO:0000269|PubMed:12176367,
CC       ECO:0000269|PubMed:15546861, ECO:0000269|PubMed:16549782,
CC       ECO:0000269|PubMed:16892053}.
CC   -!- CATALYTIC ACTIVITY: [a protein]-serine/threonine phosphate + H(2)O
CC       = [a protein]-serine/threonine + phosphate.
CC       {ECO:0000269|PubMed:11969423}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:11969423, ECO:0000269|Ref.9};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:11969423, ECO:0000269|Ref.9};
CC       Note=Binds 2 magnesium or manganese ions per subunit.
CC       {ECO:0000269|PubMed:11969423, ECO:0000269|Ref.9};
CC   -!- ENZYME REGULATION: Autoinhibited. In the autoinhibited state, the
CC       TPR domain interacts with the catalytic region and prevents
CC       substrate access to the catalytic pocket. Allosterically activated
CC       by various polyunsaturated fatty acids, free long-chain fatty-
CC       acids and long-chain fatty acyl-CoA esters, arachidonic acid being
CC       the most effective activator. HSP90A and probably RAC1, GNA12 and
CC       GNA13 can also release the autoinhibition by the TPR repeat.
CC       Activation by RAC1, GNA12 and GNA13 is synergistic with the one
CC       produced by fatty acids binding. Inhibited by okadaic acid.
CC       {ECO:0000269|PubMed:11523989, ECO:0000269|PubMed:11969423,
CC       ECO:0000269|PubMed:16549782}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=12.1 uM for MAPT/TAU (at pH 7.4 and 30 degrees Celsius)
CC         {ECO:0000269|PubMed:15546861};
CC   -!- SUBUNIT: Part of a complex with HSP90/HSP90AA1 and steroid
CC       receptors. Interacts with CDC16, CDC27. Interacts with KLHDC10
CC       (via the 6 Kelch repeats); inhibits the phosphatase activity on
CC       MAP3K5. Interacts (via TPR repeats) with HSP90AA1 (via TPR repeat-
CC       binding motif) or HSPA1A/HSPA1B; the interaction is direct and
CC       activates the phosphatase activity. Dissociates from HSPA1A/HSPA1B
CC       and HSP90AA1 in response to arachidonic acid. Interacts with ATM
CC       and ATR; both interactions are induced by DNA damage and enhance
CC       ATM and ATR kinase activity. Interacts with RAD17; reduced by DNA
CC       damage. Interacts with nuclear receptors such as NR3C1/GCR and
CC       PPARG (activated by agonist); regulates their transactivation
CC       activities. Interacts (via TPR repeats) with S100 proteins S100A1,
CC       S100A2, S100A6, S100B and S100P; the interactions are calcium-
CC       dependent, strongly activate PPP5C phosphatase activity and
CC       compete with HSP90AA1 and MAP3K5 interactions. Interacts with
CC       SMAD2 and SMAD3 but not with SMAD1; decreases SMAD3
CC       phosphorylation and protein levels. Interacts (via TPR repeats)
CC       with CRY1 and CRY2; the interaction with CRY2 downregulates the
CC       phosphatase activity on CSNK1E. Interacts (via TPR repeats) with
CC       the active form of RAC1, GNA12 or GNA13; these interactions
CC       activate the phosphatase activity and translocate PPP5C to the
CC       cell membrane. {ECO:0000269|PubMed:12176367,
CC       ECO:0000269|PubMed:16549782, ECO:0000269|PubMed:16790549,
CC       ECO:0000269|Ref.9}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12176367}.
CC       Cytoplasm {ECO:0000269|PubMed:12176367}. Membrane {ECO:0000250}.
CC       Note=Predominantly nuclear. But also present in the cytoplasm.
CC   -!- TISSUE SPECIFICITY: Predominantly found in brain and, in lower
CC       levels, in testis, but was nearly undetectable in spleen, lung,
CC       skeletal muscle, kidney and liver. {ECO:0000269|PubMed:15546861}.
CC   -!- PTM: Activated by at least two different proteolytic cleavages
CC       producing a 56 kDa and a 50 kDa form. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the PPP phosphatase family. PP-5 (PP-T)
CC       subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 3 TPR repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00339}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X77237; CAA54454.1; -; mRNA.
DR   PIR; A55346; A55346.
DR   RefSeq; NP_113917.1; NM_031729.1.
DR   UniGene; Rn.6107; -.
DR   PDB; 4JA7; X-ray; 2.00 A; A=16-499.
DR   PDB; 4JA9; X-ray; 2.30 A; A=16-499.
DR   PDBsum; 4JA7; -.
DR   PDBsum; 4JA9; -.
DR   ProteinModelPortal; P53042; -.
DR   SMR; P53042; 23-499.
DR   DIP; DIP-61212N; -.
DR   STRING; 10116.ENSRNOP00000023078; -.
DR   PRIDE; P53042; -.
DR   Ensembl; ENSRNOT00000023078; ENSRNOP00000023078; ENSRNOG00000016907.
DR   GeneID; 65179; -.
DR   KEGG; rno:65179; -.
DR   UCSC; RGD:68415; rat.
DR   CTD; 5536; -.
DR   RGD; 68415; Ppp5c.
DR   eggNOG; COG0639; -.
DR   GeneTree; ENSGT00530000063173; -.
DR   HOGENOM; HOG000172698; -.
DR   HOVERGEN; HBG000216; -.
DR   InParanoid; P53042; -.
DR   KO; K04460; -.
DR   OMA; MNRVYGF; -.
DR   OrthoDB; EOG7V49Z3; -.
DR   PhylomeDB; P53042; -.
DR   TreeFam; TF105562; -.
DR   BRENDA; 3.1.3.16; 5301.
DR   NextBio; 614076; -.
DR   PRO; PR:P53042; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   ExpressionAtlas; P53042; baseline.
DR   Genevisible; P53042; RN.
DR   GO; GO:0071944; C:cell periphery; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0005829; C:cytosol; IDA:RGD.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043005; C:neuron projection; IDA:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005654; C:nucleoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:RGD.
DR   GO; GO:0043204; C:perikaryon; IDA:RGD.
DR   GO; GO:1990635; C:proximal dendrite; IDA:RGD.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; IDA:RGD.
DR   GO; GO:0031072; F:heat shock protein binding; IPI:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008017; F:microtubule binding; IDA:RGD.
DR   GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IEA:Ensembl.
DR   GO; GO:0004871; F:signal transducer activity; IEA:Ensembl.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IEP:RGD.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEP:RGD.
DR   GO; GO:0016576; P:histone dephosphorylation; IDA:RGD.
DR   GO; GO:0060548; P:negative regulation of cell death; IMP:RGD.
DR   GO; GO:1901215; P:negative regulation of neuron death; IMP:RGD.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IMP:RGD.
DR   GO; GO:2000324; P:positive regulation of glucocorticoid receptor signaling pathway; IMP:RGD.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:RGD.
DR   GO; GO:0051291; P:protein heterooligomerization; IPI:RGD.
DR   GO; GO:0051259; P:protein oligomerization; IDA:RGD.
DR   GO; GO:0010288; P:response to lead ion; IEP:RGD.
DR   GO; GO:0043278; P:response to morphine; IEA:Ensembl.
DR   Gene3D; 1.25.40.10; -; 1.
DR   Gene3D; 3.60.21.10; -; 1.
DR   InterPro; IPR004843; Calcineurin-like_PHP_apaH.
DR   InterPro; IPR029052; Metallo-depent_PP-like.
DR   InterPro; IPR013235; PPP_dom.
DR   InterPro; IPR006186; Ser/Thr-sp_prot-phosphatase.
DR   InterPro; IPR011236; Ser/Thr_PPase_5.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom.
DR   InterPro; IPR001440; TPR_1.
DR   InterPro; IPR019734; TPR_repeat.
DR   PANTHER; PTHR11668:SF12; PTHR11668:SF12; 1.
DR   Pfam; PF00149; Metallophos; 1.
DR   Pfam; PF08321; PPP5; 1.
DR   Pfam; PF00515; TPR_1; 2.
DR   PRINTS; PR00114; STPHPHTASE.
DR   SMART; SM00156; PP2Ac; 1.
DR   SMART; SM00028; TPR; 3.
DR   SUPFAM; SSF56300; SSF56300; 1.
DR   PROSITE; PS00125; SER_THR_PHOSPHATASE; 1.
DR   PROSITE; PS50005; TPR; 3.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm; Hydrolase;
KW   Magnesium; Manganese; Membrane; Metal-binding; Nucleus;
KW   Protein phosphatase; Reference proteome; Repeat; TPR repeat.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P53041}.
FT   CHAIN         2    499       Serine/threonine-protein phosphatase 5.
FT                                /FTId=PRO_0000058897.
FT   REPEAT       28     61       TPR 1.
FT   REPEAT       62     95       TPR 2.
FT   REPEAT       96    129       TPR 3.
FT   REGION      200    499       Catalytic.
FT   REGION      303    304       Substrate binding. {ECO:0000250}.
FT   REGION      495    499       Required for autoinhibition.
FT   ACT_SITE    304    304       Proton donor/acceptor. {ECO:0000250}.
FT   METAL       242    242       Magnesium or manganese 1.
FT                                {ECO:0000269|Ref.9}.
FT   METAL       244    244       Magnesium or manganese 1.
FT                                {ECO:0000269|Ref.9}.
FT   METAL       271    271       Magnesium or manganese 1.
FT                                {ECO:0000269|Ref.9}.
FT   METAL       271    271       Magnesium or manganese 2.
FT                                {ECO:0000269|Ref.9}.
FT   METAL       303    303       Magnesium or manganese 2.
FT                                {ECO:0000269|Ref.9}.
FT   METAL       352    352       Magnesium or manganese 2.
FT                                {ECO:0000269|Ref.9}.
FT   METAL       427    427       Magnesium or manganese 2.
FT                                {ECO:0000269|Ref.9}.
FT   BINDING     244    244       Substrate. {ECO:0000250}.
FT   BINDING     275    275       Substrate. {ECO:0000250}.
FT   BINDING     400    400       Substrate. {ECO:0000250}.
FT   BINDING     427    427       Substrate. {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P53041}.
FT   MUTAGEN      29     29       E->A: No effect on phosphatase activity.
FT                                {ECO:0000269|PubMed:11523989}.
FT   MUTAGEN      32     32       K->A: No effect on phosphatase activity.
FT                                {ECO:0000269|PubMed:11523989}.
FT   MUTAGEN      40     40       K->A: Slightly reduces activation by
FT                                arachidonic acid.
FT   MUTAGEN      56     56       E->A: No effect on phosphatase activity.
FT                                {ECO:0000269|PubMed:11523989}.
FT   MUTAGEN      63     63       I->A: No effect on phosphatase activity.
FT                                {ECO:0000269|PubMed:11523989}.
FT   MUTAGEN      74     74       R->A: No effect on phosphatase activity.
FT                                {ECO:0000269|PubMed:11523989}.
FT   MUTAGEN      76     76       E->A: Increases basal phosphatase
FT                                activity. {ECO:0000269|PubMed:11523989}.
FT   MUTAGEN      77     77       C->A: No effect on phosphatase activity.
FT                                {ECO:0000269|PubMed:11523989}.
FT   MUTAGEN      80     80       Y->A: No effect on phosphatase activity.
FT                                {ECO:0000269|PubMed:11523989}.
FT   MUTAGEN      93     93       K->E: Loss of inhibition of KCNH2 channel
FT                                stimulation.
FT                                {ECO:0000269|PubMed:16549782}.
FT   MUTAGEN      97     97       K->A: No effect on phosphatase activity.
FT                                {ECO:0000269|PubMed:11523989}.
FT   MUTAGEN     101    101       R->A: No effect on phosphatase activity.
FT                                {ECO:0000269|PubMed:11523989}.
FT   MUTAGEN     126    126       K->A: Loss of inhibition of KCNH2 channel
FT                                stimulation.
FT                                {ECO:0000269|PubMed:16549782}.
FT   MUTAGEN     451    451       Y->A: Insensitive to okadaic acid.
FT                                {ECO:0000269|PubMed:16549782}.
FT   HELIX        24     40       {ECO:0000244|PDB:4JA7}.
FT   HELIX        44     57       {ECO:0000244|PDB:4JA7}.
FT   HELIX        62     74       {ECO:0000244|PDB:4JA7}.
FT   HELIX        78     91       {ECO:0000244|PDB:4JA7}.
FT   HELIX        96    108       {ECO:0000244|PDB:4JA7}.
FT   HELIX       112    125       {ECO:0000244|PDB:4JA7}.
FT   HELIX       130    148       {ECO:0000244|PDB:4JA7}.
FT   HELIX       161    164       {ECO:0000244|PDB:4JA7}.
FT   HELIX       167    169       {ECO:0000244|PDB:4JA7}.
FT   HELIX       188    199       {ECO:0000244|PDB:4JA7}.
FT   HELIX       206    221       {ECO:0000244|PDB:4JA7}.
FT   STRAND      225    229       {ECO:0000244|PDB:4JA7}.
FT   STRAND      236    240       {ECO:0000244|PDB:4JA7}.
FT   HELIX       247    257       {ECO:0000244|PDB:4JA7}.
FT   STRAND      262    264       {ECO:0000244|PDB:4JA9}.
FT   STRAND      266    270       {ECO:0000244|PDB:4JA7}.
FT   STRAND      273    276       {ECO:0000244|PDB:4JA7}.
FT   HELIX       279    292       {ECO:0000244|PDB:4JA7}.
FT   TURN        294    296       {ECO:0000244|PDB:4JA7}.
FT   STRAND      297    300       {ECO:0000244|PDB:4JA7}.
FT   HELIX       307    313       {ECO:0000244|PDB:4JA7}.
FT   HELIX       315    322       {ECO:0000244|PDB:4JA7}.
FT   HELIX       325    335       {ECO:0000244|PDB:4JA7}.
FT   STRAND      340    344       {ECO:0000244|PDB:4JA7}.
FT   TURN        345    347       {ECO:0000244|PDB:4JA7}.
FT   STRAND      348    353       {ECO:0000244|PDB:4JA7}.
FT   STRAND      357    359       {ECO:0000244|PDB:4JA9}.
FT   HELIX       363    367       {ECO:0000244|PDB:4JA7}.
FT   STRAND      372    374       {ECO:0000244|PDB:4JA7}.
FT   STRAND      377    379       {ECO:0000244|PDB:4JA7}.
FT   HELIX       380    386       {ECO:0000244|PDB:4JA7}.
FT   STRAND      391    397       {ECO:0000244|PDB:4JA7}.
FT   STRAND      401    406       {ECO:0000244|PDB:4JA7}.
FT   HELIX       408    418       {ECO:0000244|PDB:4JA7}.
FT   STRAND      422    425       {ECO:0000244|PDB:4JA7}.
FT   STRAND      433    437       {ECO:0000244|PDB:4JA7}.
FT   HELIX       438    440       {ECO:0000244|PDB:4JA7}.
FT   STRAND      442    445       {ECO:0000244|PDB:4JA7}.
FT   HELIX       451    453       {ECO:0000244|PDB:4JA7}.
FT   STRAND      459    465       {ECO:0000244|PDB:4JA7}.
FT   STRAND      468    476       {ECO:0000244|PDB:4JA7}.
FT   TURN        486    489       {ECO:0000244|PDB:4JA7}.
FT   HELIX       492    494       {ECO:0000244|PDB:4JA9}.
SQ   SEQUENCE   499 AA;  56917 MW;  720A7FB7AFC701D2 CRC64;
     MAMAEGERTE CAEPPRDEPP AEGTLKRAEE LKTQANDYFK AKDYENAIKF YSQAIELNPS
     NAIYYGNRSL AYLRTECYGY ALGDATRAIE LDKKYIKGYY RRAASNMALG KFRAALRDYE
     TVVKVKPNDK DAKMKYQECS KIVKQKAFER AIAGDEHRRS VVDSLDIESM TIEDEYSGPK
     LEDGKVTITF MKDLMQWYKD QKKLHRKCAY QILVQVKEVL CKLSTLVETT LKETEKITVC
     GDTHGQFYDL LNIFELNGLP SETNPYIFNG DFVDRGSFSV EVILTLFGFK LLYPDHFHLL
     RGNHETDNMN QIYGFEGEVK AKYTAQMYEL FSEVFEWLPL AQCINGKVLI MHGGLFSEDG
     VTLDDIRKIE RNRQPPDSGP MCDLLWSDPQ PQNGRSVSKR GVSCQFGPDV TKAFLEENQL
     DYIIRSHEVK AEGYEVAHGG RCVTVFSAPN YCDQMGNKAS YIHLQGSDLR PQFHQFTAVP
     HPNVKPMAYA NTLLQLGMM
//
